Targeting myofibroblastic cancer-associated fibroblasts (myCAFs): a promising strategy for overcoming tumor progression and immunotherapy resistance DOI Creative Commons

Danting Wang,

Zhigang Chen

Visualized Cancer Medicine, Journal Year: 2025, Volume and Issue: 6, P. 4 - 4

Published: Jan. 1, 2025

Cancer-associated fibroblasts (CAFs), as the dominant stromal cell population in tumor microenvironment (TME), exhibit substantial heterogeneity, with subtypes such myofibroblastic cancer-associated (myCAFs) and inflammatory (iCAFs) playing distinct roles cancer progression. MyCAFs, defined by elevated ACTA2 expression, are particularly significant promoting growth, remodeling stroma, contributing to an immunosuppressive TME. Despite advances understanding CAF precise role of myCAFs invasion, metastasis, resistance therapies, especially immunotherapy, remains underexplored. This perspective highlights recent insights into myCAF functions within TME, emphasizing their potential therapeutic targets. By disrupting formation or combining myCAF-targeting approaches there is a promise for improving treatment outcomes overcoming immunotherapy cancer.

Language: Английский

For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy DOI Creative Commons

Soroush Karimi,

Roksana Bakhshali,

Soheil Bolandi

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101626 - 101626

Published: March 1, 2025

Cancer treatment is challenged by the tumor microenvironment (TME), which promotes drug resistance and cancer cell growth. This review offers a comprehensive innovative perspective on how nanomedicine can modify TME to enhance therapy. Strategies include using nanoparticles improve oxygenation, adjust acidity, alter extracellular matrix, making treatments more effective. Additionally, immune responses activating cells reducing suppression within tumors. By integrating these approaches with existing therapies, such as chemotherapy radiotherapy, show promise in overcoming traditional barriers. The discusses changes effectiveness of itself, creating reciprocal relationship that boosts overall efficacy. We also highlight novel strategies aimed at exploiting TME, leveraging nanoparticle-based for targeted therapy through precise modulation.

Language: Английский

Citations

2
Targeting myofibroblastic cancer-associated fibroblasts (myCAFs): a promising strategy for overcoming tumor progression and immunotherapy resistance DOI Creative Commons

Danting Wang,

Zhigang Chen

Visualized Cancer Medicine, Journal Year: 2025, Volume and Issue: 6, P. 4 - 4

Published: Jan. 1, 2025

Cancer-associated fibroblasts (CAFs), as the dominant stromal cell population in tumor microenvironment (TME), exhibit substantial heterogeneity, with subtypes such myofibroblastic cancer-associated (myCAFs) and inflammatory (iCAFs) playing distinct roles cancer progression. MyCAFs, defined by elevated ACTA2 expression, are particularly significant promoting growth, remodeling stroma, contributing to an immunosuppressive TME. Despite advances understanding CAF precise role of myCAFs invasion, metastasis, resistance therapies, especially immunotherapy, remains underexplored. This perspective highlights recent insights into myCAF functions within TME, emphasizing their potential therapeutic targets. By disrupting formation or combining myCAF-targeting approaches there is a promise for improving treatment outcomes overcoming immunotherapy cancer.

Language: Английский

Citations

0